(19)
(11) EP 4 132 511 A1

(12)

(43) Date of publication:
15.02.2023 Bulletin 2023/07

(21) Application number: 21784898.5

(22) Date of filing: 06.04.2021
(51) International Patent Classification (IPC): 
A61K 31/4045(2000.01)
A61K 47/02(1990.01)
A61K 31/5415(2000.01)
A61P 29/00(2000.01)
(52) Cooperative Patent Classification (CPC):
A61P 29/00; A61K 31/5415; A61K 9/2009; A61K 9/205; A61K 9/209; A61K 31/724; A61K 31/4196; A61K 33/10
 
C-Sets:
  1. A61K 31/724, A61K 2300/00;
  2. A61K 31/5415, A61K 2300/00;
  3. A61K 31/4196, A61K 2300/00;
  4. A61K 33/10, A61K 2300/00;

(86) International application number:
PCT/US2021/026027
(87) International publication number:
WO 2021/207253 (14.10.2021 Gazette 2021/41)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 06.04.2020 US 202063006023 P
06.04.2020 US 202016841436
07.04.2020 US 202016842063
06.05.2020 US 202016867929

(71) Applicant: Axsome Therapeutics, Inc.
New York, NY 10007 (US)

(72) Inventor:
  • TABUTEAU, Herriot
    New York, New York 10007 (US)

(74) Representative: Murgitroyd & Company 
Murgitroyd House 165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)

   


(54) PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM